Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
Journal of the European Academy of Dermatology and Venereology : JEADV|January 16, 2014
Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapyB E Strober, Y Poulin, C Teller, et al.
Photochemistry and Photobiology|December 1, 1993
Collagen alterations in chronically sun-damaged human skinE Schwartz, F A Cruickshank, C C Christensen, et al.
The New England Journal of Medicine|August 6, 1987
Diagnosis of pseudoxanthoma elasticum by scar biopsy in patients without characteristic skin lesionsM Lebwohl, R G Phelps, L Yannuzzi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 25, 2013
Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACHY Poulin, J J Crowley, R G Langley, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1991
Acanthosis Nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findingsA Dunaif, G Green, R G Phelps, et al.
Journal of the American Academy of Dermatology|June 1, 1994
Abnormalities of fibrillin in acquired cutis laxaM G Lebwohl, E Schwartz, L Jacobs, et al.
Archives of Dermatology|March 20, 2001
The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership surveyG Krueger, J Koo, M Lebwohl, et al.
Archives of Dermatological Research|January 1, 1993
Abnormalities of connective tissue components in lesional and non-lesional tissue of patients with pseudoxanthoma elasticumM Lebwohl, E Schwartz, G Lemlich, et al.
The British Journal of Dermatology|October 17, 2015
Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month studyC Garbe, N Basset-Seguin, Y Poulin, et al.
The British Journal of Dermatology|June 29, 2020
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trialR B Warren, A Blauvelt, Y Poulin, et al.
Pageof 16